Shay Elkins, a patient with triple negative breast cancer, shares her experience of relapse six months post-treatment, eventually leading her to seek a second opinion for her recurring symptoms. Dr. Noor Abuhadra discusses second-line treatment options for metastatic triple negative breast cancer, emphasizing newer therapies like antibody drug conjugates and PARP inhibitors, and highlights the evolving landscape that offers hope for patients.
